Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Xeroderma pigmentosum (XP) encompasses a group of rare diseases characterized in most cases by malfunction of nucleotide excision repair (NER), which results in an increased sensitivity to UV radiation in affected individuals. Approximately 25–30% of XP patients present with neurological symptoms, such as sensorineural deafness, mental deterioration and ataxia. Although it is known that dysfunctional DNA repair is the primary pathogenesis in XP, growing evidence suggests that mitochondrial pathophysiology may also occur. This appears to be secondary to dysfunctional NER but may contribute to the neurodegenerative process in these patients. The available pharmacological treatments in XP mostly target the dermal manifestations of the disease. In the present review, we outline how current understanding of the pathophysiology of XP could be used to develop novel therapies to counteract the neurological symptoms. Moreover, the coexistence of cancer and neurodegeneration present in XP led us to focus on possible new avenues targeting mitochondrial pathophysiology. Linked Articles: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative DNA damage: mechanisms, mutation, and disease
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0752rev · Cited by 3,245 · cited 1×
“Moreover, when ROS generation is not efficiently counteracted by the endogenous antioxidant systems, it increases and subsequently leads to deleterious effects on DNA, lipids and proteins (Cooke et al., 2003; Hayashi, 2009).”
BackgroundThe XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase η
Masutani, C., Kusumoto, R., Yamada, A., Dohmae, N., Yokoi, M., Yuasa, M., Araki, M., Iwai, S., Takio, K., & Hanaoka, F. (1999) · Nature · doi:10.1038/21447 · Cited by 1,292
Mitochondrial damage induced by conditions of oxidative stress
Kowaltowski, A. J., & Vercesi, A. E. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00216-0 · Cited by 866 · cited 1×
“This leads to a further increase in oxidative stress (Kowaltowski and Vercesi, 1999).”
BackgroundDefective Mitophagy in XPA via PARP-1 Hyperactivation and NAD+/SIRT1 Reduction
Fang, E. F., Scheibye-Knudsen, M., Brace, L. E., Kassahun, H., SenGupta, T., Nilsen, H., Mitchell, J. R., Croteau, D. L., & Bohr, V. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.026 · Cited by 711
Lehman, A. R., Kirk-Bell, S., Arlett, C. F., Paterson, M. C., Lohman, P. H., de Weerd-Kastelein, E. A., & Bootsma, D. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.1.219 · Cited by 614 · cited 2×
“variant (XPV) harbour mutations in the DNA polymerase which is involved in DNA synthesis after UV radiation-related damage (Lehmann et al., 1975; Masutani et al., 1999).”
BackgroundShining a light on xeroderma pigmentosum
DiGiovanna, J. J., & Kraemer, K. H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.426 · Cited by 547 · cited 2×
“This may manifest with severe skin burning and blistering in infants, but not all patients exhibit this acute abnormal reaction to sunlight (DiGiovanna and Kraemer, 2012; Sethi et al., 2013; Fassihi et al., 2016).”
BackgroundBradford, P. T., Goldstein, A. M., Tamura, D., Khan, S. G., Ueda, T., Boyle, J., Oh, K.-S., Imoto, K., Inui, H., Moriwaki, S.-I., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.083022 · Cited by 480 · cited 3×
“The mean age of death of affected patients has been reported as 29 years, compared to 37 years in patients without neurodegeneration (Bradford et al., 2011).”
BackgroundMammalian Mitochondrial Complex I: Biogenesis, Regulation, and Reactive Oxygen Species Generation
Koopman, W. J. H., Nijtmans, L. G. J., Dieteren, C. E. J., Roestenberg, P., Valsecchi, F., Smeitink, J. A. M., & Willems, P. H. G. M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2743 · Cited by 411
Yarosh, D., Klein, J., O'Connor, A., Hawk, J., Rafal, E., & Wolf, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04214-8 · Cited by 390
Defective DNA Repair and Neurodegenerative Disease
Rass, U., Ahel, I., & West, S. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.043 · Cited by 358 · cited 2×
“…nervous system results in a wide range of symptoms including (i) progressive cognitive impairment, (ii) sensorineural hearing loss, (iii) ataxia, (iv) pyramidal and (v) extrapyramidal tract signs and (vi) areflexia (Rass et al., 2007; Niedernhofer, 2008; Lehmann et al., 2011; Fassihi et al., 2016).”
Background
Cited by
DNA Damage and Associated DNA Repair Defects in Disease and Premature Aging
Tiwari, V., & Wilson, D. M. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.06.005 · Cited by 244
DNA damage and transcription stress
Milano, L., Gautam, A., & Caldecott, K. W. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.11.014 · Cited by 88
DNA Damage-Induced Neurodegeneration in Accelerated Ageing and Alzheimer’s Disease
Wang, H., Lautrup, S., Caponio, D., Zhang, J., & Fang, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136748 · Cited by 55
Sunlight, Vitamin D, and Xeroderma Pigmentosum
Martens, M. C., Emmert, S., & Boeckmann, L. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-46227-7_16 · Cited by 24
Metadata
- Authors
- Abeti, R., Zeitlberger, A., Peelo, C., Fassihi, H., Sarkany, R. P. E., Lehmann, A. R., & Giunti, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2019-01-23
- Volume
- 176
- Issue
- 22
- Pages
- 4293-4301
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2902029936
- Cited by
- 38
- References
- 18
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.